POM-V Prescription Required Companion Animal

Temprace 0.5 mg/ml Solution for Injection for Dogs and Cats

Active ingredient: Acepromazine

Form

Injection

Species

Cats Dogs

Manufacturer

Le Vet Beheer B.V.

VMD MA No.

41821/4053

What it's used for

For sedation of horses

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Acepromazine

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Temprace 0.5 mg/ml Solution for Injection for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

For sedation of horses

To ensure a correct dosage, body weight should be determined as accurately as possible.
Premedication: mg acepromazine per kg bodyweight, corresponding to
0.6−2.5 ml veterinary medicinal product per 10 kg bodyweight
Other uses: mg acepromazine per kg bodyweight, corresponding to
1.25−2.5 ml veterinary medicinal product per 10 kg bodyweight.
The maximum dose that should be given is 4 mg acepromazine per animal.
Normally single doses of acepromazine are administered (see section 3.5, Special
precautions for safe use in the target species). Following acepromazine administration,
the amount of anaesthetic necessary to induce anaesthesia may be considerably
reduced.

Revised August 2025
AN: 01039/2024 & 01043/2024
Take adequate precautions to maintain sterility. Avoid the introduction of contamination
during use. Should any apparent growth or discolouration occur, discard the veterinary
medicinal product.
The maximum number of vial punctures when using needle sizes 21G and 23G should
not exceed 100 and when using a 18G needle, the maximum should not exceed 40.

Do not use in pregnant animals.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
Do not use on a long term basis in individual animals.
See also section 3.8.

Revised August 2025
AN: 01039/2024 & 01043/2024

Dogs, cats:
Undetermined frequency
(cannot be estimated from the
available data)
Arrhythmia
a
a
Following rapid intravenous injection. See also section 3.5 (Special precautions for safe
use in the target species).
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

Since the individual response to acepromazine may be variable, reliable sedation may
not be achieved in some animals. In these individuals, other drugs or drug combinations
should be considered.
In the absence of suitable studies regarding efficacy, the veterinary medicinal product
should not be administered via the subcutaneous or intramuscular routes.

Special precautions for safe use in the target species:
Acepromazine is hypotensive and can cause a transient reduction in haematocrit. The
veterinary medicinal product should therefore be administered with great caution, and at
low dose rates only, to animals in states of hypovolaemia, anaemia and shock or with
cardiovascular disease. Rehydration should precede acepromazine administration.
Acepromazine may cause hypothermia due to depression of the thermoregulatory centre
and peripheral vasodilation.
Acepromazine has negligible analgesic effects. Painful activities should be avoided when
handling tranquillized animals.
In some dogs, particularly Boxers and other short-nosed breeds, spontaneous fainting or
syncope may occur due to sinoatrial block caused by excessive vagal tone. An attack
may be precipitated by an injection of acepromazine, so a low dose should be used.
Where there is a history of this type of syncope, or if it is suspected because of excessive
sinus arrhythmia, it may be advantageous to control the dysrhythmia with atropine given
just before the acepromazine.
In dogs with the (also called MDR1) mutation, acepromazine tends to cause
more profound and prolonged sedation. In these dogs the dose should be reduced by
25%-50%.
Large breeds: It has been noted that large breeds of dog are particularly sensitive to
acepromazine and the minimum dose possible should be used in these breeds.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
This veterinary medicinal product contains a potent sedative, care should be taken, when
handling and administering the veterinary medicinal product, to avoid accidental self-
exposure.
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician but DO NOT DRIVE as sedation may occur.
Symptomatic treatment may be required.
If accidental eye contact occurs, flush gently with fresh running water for 15 minutes and
seek medical advice if any irritation persists.
In the event of accidental skin contact, contaminated clothing should be removed and the
area washed with large amounts of soap and water. Medical advice should be sought if
irritation persists.
Wash hands and exposed skin thoroughly after use.
Special precautions for the protection of the environment:
Not applicable.

Revised August 2025
AN: 01039/2024 & 01043/2024

Acepromazine is additive to the actions of other CNS depressants and will potentiate
general anaesthesia (see section 3.9).
Do not use this veterinary medicinal product in conjunction with organophosphates and/or
procaine hydrochloride, as it may enhance activity and potential toxicity.

Keep the vial in the outer carton in order to protect from light.

Not applicable.
4.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.